These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 26712227)

  • 1. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
    Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
    J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.
    Martinelli G; Schmitz SF; Utiger U; Cerny T; Hess U; Bassi S; Okkinga E; Stupp R; Stahel R; Heizmann M; Vorobiof D; Lohri A; Dietrich PY; Zucca E; Ghielmini M
    J Clin Oncol; 2010 Oct; 28(29):4480-4. PubMed ID: 20697092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
    Moccia AA; Taverna C; Schär S; Vanazzi A; Rondeau S; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Raats J; Rauch D; Vorobiof DA; Lohri A; Ruegsegger C; Biaggi Rudolf C; Rusterholz C; Hayoz S; Ghielmini M; Zucca E
    Blood Adv; 2020 Dec; 4(23):5951-5957. PubMed ID: 33275769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
    Ardeshna KM; Qian W; Smith P; Braganca N; Lowry L; Patrick P; Warden J; Stevens L; Pocock CF; Miall F; Cunningham D; Davies J; Jack A; Stephens R; Walewski J; Ferhanoglu B; Bradstock K; Linch DC
    Lancet Oncol; 2014 Apr; 15(4):424-35. PubMed ID: 24602760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
    Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD;
    Cancer Med; 2019 Nov; 8(16):6955-6966. PubMed ID: 31573746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
    Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U;
    J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
    Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
    Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
    Salles G; Seymour JF; Offner F; López-Guillermo A; Belada D; Xerri L; Feugier P; Bouabdallah R; Catalano JV; Brice P; Caballero D; Haioun C; Pedersen LM; Delmer A; Simpson D; Leppa S; Soubeyran P; Hagenbeek A; Casasnovas O; Intragumtornchai T; Fermé C; da Silva MG; Sebban C; Lister A; Estell JA; Milone G; Sonet A; Mendila M; Coiffier B; Tilly H
    Lancet; 2011 Jan; 377(9759):42-51. PubMed ID: 21176949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.
    Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova J; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
    Leuk Lymphoma; 2016 May; 57(5):1094-103. PubMed ID: 26293000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
    Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
    J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
    Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
    Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
    Bachy E; Seymour JF; Feugier P; Offner F; López-Guillermo A; Belada D; Xerri L; Catalano JV; Brice P; Lemonnier F; Martin A; Casasnovas O; Pedersen LM; Dorvaux V; Simpson D; Leppa S; Gabarre J; da Silva MG; Glaisner S; Ysebaert L; Vekhoff A; Intragumtornchai T; Le Gouill S; Lister A; Estell JA; Milone G; Sonet A; Farhi J; Zeuner H; Tilly H; Salles G
    J Clin Oncol; 2019 Nov; 37(31):2815-2824. PubMed ID: 31339826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.
    Morschhauser F; Radford J; Van Hoof A; Botto B; Rohatiner AZ; Salles G; Soubeyran P; Tilly H; Bischof-Delaloye A; van Putten WL; Kylstra JW; Hagenbeek A
    J Clin Oncol; 2013 Jun; 31(16):1977-83. PubMed ID: 23547079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Ribrag V; Tilly H; Casasnovas O; Bosly A; Bouabdallah R; Delarue R; Boue F; Bron D; Feugier P; Haioun C; Offner F; Coiffier B
    Eur J Cancer; 2013 Mar; 49(4):904-10. PubMed ID: 23273434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).
    Barta SK; Li H; Hochster HS; Hong F; Weller E; Gascoyne RD; Habermann TM; Gordon LI; Colocci N; Bengtson EM; Horning SJ; Kahl BS
    Cancer; 2016 Oct; 122(19):2996-3004. PubMed ID: 27351685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.
    Jurczak W; Moreira I; Kanakasetty GB; Munhoz E; Echeveste MA; Giri P; Castro N; Pereira J; Akria L; Alexeev S; Osmanov E; Zhu P; Alexandrova S; Zubel A; Harlin O; Amersdorffer J
    Lancet Haematol; 2017 Aug; 4(8):e350-e361. PubMed ID: 28712941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
    Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
    Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.